Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i
Introduction A high proportion of Canadian patients with acute myocardial infarction (AMI) do not achieve the threshold low-density lipoprotein cholesterol (LDL-C) levels recommended by the Canadian Cardiovascular Society in 2021. This increases the risk of subsequent atherosclerotic cardiovascular disease (ASCVD) events. Here, we assess LDL-C levels and threshold achievement among patients by lipid-lowering therapies (LLT) received post-AMI. Methods A retrospective cohort study of patients identified with AMI between 2015 and 2019 was conducted using administrative health databases in Alberta, Canada. Patients were grouped by their highest-intensity LLT post-AMI (proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) + another LLT; PCSK9i alone; ezetimibe + statin; statins (high, moderate, low intensity); or ezetimibe alone), and available LDL-C levels were examined in the year before and after LLT dispense date. Results The cohort included 15,283 patients. In patients on PCSK9i + LLT, the median [95% confidence interval (CI)] LDL-C levels decreased from 2.7 (2.3–3.4) before to 0.9 (0.5–1.2) mmol/l after treatment, the largest decrease among treatment groups. In the ezetimibe + statin and high-intensity statin groups, median (95% CI) values after treatment were 1.5 (1.5–1.6) and 1.4 (1.4–1.4) mmol/l, respectively. The proportion of patients below the 1.8 mmol/l threshold increased by 77.7% in the PSCK9i + LLT group after treatment, compared to 45.4 and 32.4% in the ezetimibe + statin and high-intensity statin groups, respectively. Conclusions Intensification with PCSK9i in AMI patients results in a greater proportion of patients achieving below the recommended LDL-C threshold versus statins and or ezetimibe alone. Increased focus on achieving below the LDL-C thresholds with additional LLT as required may benefit patient cardiovascular outcomes..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cardiology and therapy - 12(2023), 2 vom: 19. Jan., Seite 327-338 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mackinnon, Erin S. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Acute myocardial infarction |
|---|
| Anmerkungen: |
© The Author(s) 2022. corrected publication 2023 |
|---|
| doi: |
10.1007/s40119-022-00300-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR051627205 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR051627205 | ||
| 003 | DE-627 | ||
| 005 | 20230525064728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230525s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40119-022-00300-7 |2 doi | |
| 035 | |a (DE-627)SPR051627205 | ||
| 035 | |a (SPR)s40119-022-00300-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mackinnon, Erin S. |e verfasserin |0 (orcid)0000-0001-9736-6970 |4 aut | |
| 245 | 1 | 0 | |a Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022. corrected publication 2023 | ||
| 520 | |a Introduction A high proportion of Canadian patients with acute myocardial infarction (AMI) do not achieve the threshold low-density lipoprotein cholesterol (LDL-C) levels recommended by the Canadian Cardiovascular Society in 2021. This increases the risk of subsequent atherosclerotic cardiovascular disease (ASCVD) events. Here, we assess LDL-C levels and threshold achievement among patients by lipid-lowering therapies (LLT) received post-AMI. Methods A retrospective cohort study of patients identified with AMI between 2015 and 2019 was conducted using administrative health databases in Alberta, Canada. Patients were grouped by their highest-intensity LLT post-AMI (proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) + another LLT; PCSK9i alone; ezetimibe + statin; statins (high, moderate, low intensity); or ezetimibe alone), and available LDL-C levels were examined in the year before and after LLT dispense date. Results The cohort included 15,283 patients. In patients on PCSK9i + LLT, the median [95% confidence interval (CI)] LDL-C levels decreased from 2.7 (2.3–3.4) before to 0.9 (0.5–1.2) mmol/l after treatment, the largest decrease among treatment groups. In the ezetimibe + statin and high-intensity statin groups, median (95% CI) values after treatment were 1.5 (1.5–1.6) and 1.4 (1.4–1.4) mmol/l, respectively. The proportion of patients below the 1.8 mmol/l threshold increased by 77.7% in the PSCK9i + LLT group after treatment, compared to 45.4 and 32.4% in the ezetimibe + statin and high-intensity statin groups, respectively. Conclusions Intensification with PCSK9i in AMI patients results in a greater proportion of patients achieving below the recommended LDL-C threshold versus statins and or ezetimibe alone. Increased focus on achieving below the LDL-C thresholds with additional LLT as required may benefit patient cardiovascular outcomes. | ||
| 650 | 4 | |a Proprotein convertase subtilisin/kexin type 9 inhibitors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lipid-lowering therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Acute myocardial infarction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Low-density lipoprotein cholesterol |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Real-world evidence |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Har, Bryan |0 (orcid)0000-0003-2760-8967 |4 aut | |
| 700 | 1 | |a Champsi, Salimah |0 (orcid)0000-0001-6205-6059 |4 aut | |
| 700 | 1 | |a Wani, Rajvi J. |0 (orcid)0000-0002-2422-7758 |4 aut | |
| 700 | 1 | |a Geyer, Lee |0 (orcid)0000-0002-3805-5483 |4 aut | |
| 700 | 1 | |a Shaw, Eileen |0 (orcid)0000-0001-6537-1898 |4 aut | |
| 700 | 1 | |a Farris, Megan S. |0 (orcid)0000-0003-0640-9512 |4 aut | |
| 700 | 1 | |a Anderson, Todd J. |0 (orcid)0000-0003-3751-6468 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiology and therapy |d Heidelberg : Springer, 2012 |g 12(2023), 2 vom: 19. Jan., Seite 327-338 |w (DE-627)SPR032874529 |w (DE-600)2700626-8 |x 2193-6544 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:2 |g day:19 |g month:01 |g pages:327-338 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40119-022-00300-7 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 2 |b 19 |c 01 |h 327-338 | ||